Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:20 AM
Ignite Modification Date:
2025-12-25 @ 12:20 AM
NCT ID:
NCT02684058
Eligibility Criteria:
Key Inclusion Criteria:
* Diagnosis of BRAF V600 mutant High Grade glioma that had relapsed, progressed or failed to respond to frontline therapy
* Diagnosis of BRAF V600 mutant Low Grade glioma with progressive disease following surgical excision, or non-surgical candidates with necessity to begin first systemic treatment because of a risk of neurological impairment with progression.
* Confirmed measurable disease
Key Exclusion Criteria:
* Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitor
* HGG patient: Cancer treatment within the past 3 weeks. LGG patient: Any systemic therapy or radiotherapy prior to enrollment
* LGG patients: history of allergic reaction or contraindications to the use of carboplatin or vincristine
* Stem cell transplant within the past 3 months
* History of heart disease
* Pregnant or lactating females
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
12 Months
Maximum Age:
17 Years
Study:
NCT02684058
Study Brief:
Protocol Section:
NCT02684058